A Pharmacokinetic Comparison of Two Oral Formulations of Petadeferitrin in Healthy Volunteers

The primary objective of this study is to evaluate the bioequivalence of two different formulations of petadeferitrin in healthy volunteers. This assessment is clinically relevant to ensure that the different dosage forms provide consistent systemic exposure. The study also aims to characterize the pharmacokinetics of the drug, specifically focusing on how the body absorbs and eliminates the substance.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers within the pediatric age range, including both males and females. The cohort is identified as a vulnerable population. Participants are characterized by the absence of iron overload resulting from thalassemia, transfusion-dependent myelodysplastic syndrome, or haemolysis.

This Phase 3 clinical trial is designed as a comparative study to evaluate the pharmacokinetics of petadeferritin administered in two distinct formulations within a healthy population. The research methodology focuses on the processes of absorption and elimination of the substance. The study protocol includes a screening visit to determine eligibility, followed by sequential study visits to monitor physiological responses, and concludes with an end-of-study visit. The total duration of participant involvement is determined by the established study schedule. Early termination from the study may occur based on predefined clinical criteria or safety protocols.

The assessment of efficacy in this phase 3 clinical trial focuses on managing iron overload resulting from thalassemia, transfusion-dependent myelodysplastic syndrome, and haemolysis.